Predictive, Preventive and Personalised Medicine as the hardcore of ‘Horizon 2020’: EPMA position paper

Golubnitschaja, Olga; Kinkorová, Judita; Costigliola, Vincenzo

doi:10.1186/1878-5085-5-6

“…The European Association for Predictive, Preventive and Personalized Medicine (EPMA) promotes this integrative concept of medicine [43][44][45]69] and describes the predictive, preventative and personalized medicine (PPPM) as the medicine of the future. PPPM is one of the main strategies in BHorizon 2020^ [43,45,69]. Horizon 2020 is the biggest European Union Research and Innovation programme with a funding budget of nearly 80 billion euros over 2014 to 2020.…”

Section: Strategies and Future Paths To Personalized Psychiatrymentioning

confidence: 99%

Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry

Amare

¹

,

Schubert

²

,

Baune

³

2017

View full text Add to dashboard Cite

Personalized medicine (personalized psychiatry in a specific setting) is a new model towards individualized care, in which knowledge from genomics and other omic pillars (microbiome, epigenomes, proteome, and metabolome) will be combined with clinical data to guide efforts to new drug development and targeted prescription of the existing treatment options. In this review, we summarize pharmacogenomic studies in mood disorders that may lay the foundation towards personalized psychiatry. In addition, we have discussed the possible strategies to integrate data from omic pillars as a future path to personalized psychiatry. So far, the progress of uncovering single nucleotide polymorphisms (SNPs) underpinning treatment efficacy in mood disorders (e.g., SNPs associated with selective serotonin re-uptake inhibitors or lithium treatment response in patients with bipolar disorder and major depressive disorder) are encouraging, but not adequate. Genetic studies have pointed to a number of SNPs located at candidate genes that possibly influence response to; (a) antidepressants COMT, HTR2A, HTR1A, CNR1, SLC6A4, NPY, MAOA, IL1B, GRIK4, BDNF, GNB3, FKBP5, CYP2D6, CYP2C19, and ABCB1 and (b) mood stabilizers (lithium) 5-HTT, TPH, DRD1, FYN, INPP1, CREB1, BDNF, GSK3β, ARNTL, TIM, DPB, NR3C1, BCR, XBP1, and CACNG2. We suggest three alternative and complementary strategies to implement knowledge gained from pharmacogenomic studies. The first strategy can be to implement diagnostic, therapeutic, or prognostic genetic testing based on candidate genes or gene products. The second alternative is an integrative analysis (systems genomics approach) to combine omics data obtained from the different pillars of omics investigation, including genomics, epigenomes, proteomics, metabolomics and microbiomes. The main goal of system genomics is an identification and understanding of biological pathways, networks, and modules underlying drug-response. The third strategy aims to the development of multivariable diagnostic or prognostic algorithms (tools) combining individual's genomic information (polygenic score) with other predictors (e.g., omics pillars, neuroimaging, and clinical characteristics) to finally predict therapeutic outcomes. An integration of molecular science with that of traditional clinical practice is the way forward to drug discoveries and novel therapeutic approaches and to characterize psychiatric disorders leading to a better predictive, preventive, and personalized medicine (PPPM) in psychiatry. With future advances in the omics technology and methodological developments for data integration, the goal of PPPM in psychiatry is promising.

show abstract

“…In addition, this approach fits with the new stratification strategy necessary for controlling treatment in pharmacogenomics and also for the better definition of reference values influenced by biological variation (i.e., age and sex) [30] and other lifestyle factors (i.e., tobacco, nutrition, and so on) [1,10]. Moreover, the comparability, or the unification, of laboratory reference values [16] is required by the "mobility" of patients and the need of sharing information among different health-care units, as well as by the globalization of laboratory-related markets.…”

Section: Discussionmentioning

confidence: 99%

“…Personalized medicine is focused on tailoring medical treatments to the characteristics of patient's profile stratified by biomarkers [15][16][17]. To reach this goal, the communication among professionals, doctors, and patients should be implemented [18], with a benefit for society, industry, and patients, who can become aware of their own health care, and this may contribute to improve the adherence to treatment recommendations [19], as a recent questionnaire in Japanese population have demonstrated [20].…”

Section: Introductionmentioning

confidence: 99%

Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe

Malentacchi

¹

,

Mancini

²

,

Brandslund

³

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Developments in "-omics" are creating a paradigm shift in laboratory medicine leading to personalized medicine. This allows the increase in diagnostics and therapeutics focused on individuals rather than populations. In order to investigate whether laboratory medicine is ready to play a key role in the integration of personalized medicine in routine health care and set the state-of-the-art knowledge about personalized medicine and laboratory medicine in Europe, a questionnaire was constructed under the auspices of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and the European Society of Pharmacogenomics and Personalised Therapy (ESPT). The answers of the participating laboratory medicine professionals indicate that they are aware that personalized medicine can represent a new and promising health model, and that laboratory medicine should play a key role in supporting the implementation of personalized medicine in the clinical setting. Participants think that the current organization of laboratory medicine needs additional/relevant implementations such as (i) new technological facilities in -omics; (ii) additional training for the current personnel focused on the new methodologies; (iii) incorporation in the laboratory of new competencies in data interpretation and counseling; and (iv) cooperation and collaboration among professionals of different disciplines to integrate information according to a personalized medicine approach.

show abstract

“…Moreover, the comparability, or the unification, of laboratory reference values [16] is required by the "mobility" of patients and the need of sharing information among different health-care units, as well as by the globalization of laboratory-related markets.…”

Section: Discussionmentioning

confidence: 99%

Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe

Malentacchi

¹

,

Mancini

²

,

Brandslund

³

et al. 2015

Drug Metabolism and Personalized Therapy

View full text Add to dashboard Cite

Developments in "-omics" are creating a paradigm shift in laboratory medicine leading to personalized medicine. This allows the increase in diagnostics and therapeutics focused on individuals rather than populations. In order to investigate whether laboratory medicine is ready to play a key role in the integration of personalized medicine in routine health care and set the state-of-the-art knowledge about personalized medicine and laboratory medicine in Europe, a questionnaire was constructed under the auspices of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and the European Society of Pharmacogenomics and Personalised Therapy (ESPT). The answers of the participating laboratory medicine professionals indicate that they are aware that personalized medicine can represent a new and promising health model, and that laboratory medicine should play a key role in supporting the implementation of personalized medicine in the clinical setting. Participants think that the current organization of laboratory medicine needs additional/relevant implementations such as (i) new technological facilities in -omics; (ii) additional training for the current personnel focused on the new methodologies; (iii) incorporation in the laboratory of new competencies in data interpretation and counseling; and (iv) cooperation and collaboration among professionals of different disciplines to integrate information according to a personalized medicine approach.Brought to you by | MIT Libraries Authenticated Download Date | 5/10/18 11:36 PM 122 Malentacchi et al.: Is laboratory medicine ready for the era of personalized medicine?

show abstract

Predictive, Preventive and Personalised Medicine as the hardcore of ‘Horizon 2020’: EPMA position paper

Cited by 140 publications

References 22 publications

Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry

Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry

Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe

Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe

Contact Info

Product

Resources

About